Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Suzanne L. Topalian's publication output changed over time?
ScholarIQpublication output · 1988–2018
Output grew0% over the shown period — from 1 works in 1988 to 1 in 2018.
1
1
3
2
1
1
1
1988201020122014201520162018
What are the most-cited papers on Suzanne L. Topalian?
ScholarIQmost cited works
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure–Kunkel, Shruti Agrawal, D. G. McDonald, Georgia Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol
New England Journal of Medicine. 201212,716 CitationsOPEN ACCESS
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, Wen-Jen Hwu, Suzanne L. Topalian, Patrick Hwu, Charles G. Drake, Luis H. Camacho, John Kauh, Kunle Odunsi, Henry C. Pitot, Omid Hamid, Shailender Bhatia, Renato Martins, Keith D. Eaton, Shuming Chen, Theresa M. Salay, Suresh Alaparthy, Joseph F. Grosso, Alan J. Korman, Susan Parker, Shruti Agrawal, S. Goldberg, Drew M. Pardoll, Ashok Gupta, Jon M. Wigginton
New England Journal of Medicine. 20128,035 CitationsOPEN ACCESS
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll
Cancer Cell. 20154,269 CitationsOPEN ACCESS
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer, Charles G. Drake, Ira Wollner, John D. Powderly, Joel Picus, William H. Sharfman, Elizabeth Stankevich, Alice Pons, Theresa M. Salay, Tracee L. McMiller, Marta M. Gilson, Changyu Wang, Mark Selby, Janis M. Taube, Robert A. Anders, Lieping Chen, Alan J. Korman, Drew M. Pardoll, Israel Lowy, Suzanne L. Topalian
Journal of Clinical Oncology. 20102,950 CitationsOPEN ACCESS
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian, Janis M. Taube, Robert A. Anders, Drew M. Pardoll
Nature reviews. Cancer. 20162,759 CitationsOPEN ACCESS
Related on ScholarIQ
Bloomberg (United States)
University
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Paper
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Paper
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Paper
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Paper
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Paper